Biocosm Inc. is a biomedical research and development (R&D) corporation, established as a spin-off from Technology Holding, LLC, a company that specializes in incubating early stage innovations since 2002.
Biocosm Inc. enjoys financial and strategic, business and product development backing from established partners, and is funded by private investors. In addition to the supporting staff, Biocosm Inc. is managed by a team of highly skilled physician and scientists. Biocosm Inc. combines state-of-the-art biomedical research with innovative engineering technology.
Employ a robust and user-friendly auto injector technology to bring injectable therapy to patients at home.
Develop novel biological therapy for patients with hematologic and oncologic diseases.
Chief Executive Officer
Chief Operating Officer
Chief Technology Officer
Chief Regulatory Officer
A panel of injectors built from the novel patented auto injector technology invented by a faculty member at Brigham Young University. The first in our pipeline is terbutaline auto injector, aimed at treating patients with exacerbation of asthma and chronic obstructive pulmonary disease. Others in the pipeline include steroids and opioid overdose reversal agents.
Design of a dual-chamber auto injector for combination therapy.
Research is ongoing into novel biologics for therapy of sickle cell disease and as adjuvant to immune checkpoint inhibitor therapy for lung cancer.
A novel peptide-based advanced therapeutic for asthma (funded by the National Institute of Health).